A recent study reveals that individuals who come off blockbuster GLP-1 drugs like semaglutide or tirzepatide may regain reduced body mass at a significantly accelerated pace than those who stop conventional lifestyle regimens.
Research printed in a leading health publication demonstrates that while obese individuals can lose a large proportion of their total mass while on the medication, the weight is regained at an estimated rate of 0.8 kg per month after stopping.
"Users purchasing these treatments must be cognizant of the potential of rapid weight regain when the therapy concludes," warns lead investigator Dr. Susan Jebb.
That rate of recovery suggests a return to pre-treatment mass within about one and a half years.
Analyzing Treatments
The analysis, which looked at dozens of trials involving over 9,000 of patients, compared the effects of the injectable medications with older methods.
Researchers emphasize that people who lose weight through lifestyle changes alone typically experience a more gradual creep back—around 100 grams monthly—once they finish.
Understanding the Rapid Rebound
Experts suggest the mode of action of the injections is key to understanding the amplified regain.
GLP-1 drugs imitate a natural hormone called GLP-1, which helps regulate appetite.
"Sustained high doses of GLP-1 levels far above than the body's typical production may cause the body to produce less of its endogenous GLP-1, and may also diminish responsiveness to its actions," noted Dr. Adam Collins, a dietetics expert.
"Stopping of this medication results in appetite is uncontrolled, making excessive eating much more probable."
An Ongoing Disease?
The NHS recommend the injections for individuals with obesity-related medical conditions, accompanied by prescribed diet and exercise modifications.
A number of clinicians argue that, given the high risk of relapse, the therapy might need to be life-long.
This opinion is supported by drug manufacturers, who say that the results "emphasize the persistent character of obesity," similar to managing conditions like high blood pressure.
User Accounts
People who have come off the jabs describe a intense resurgence of appetite.
"I experienced something that goes on and I was suddenly ravenous," said one woman.
The struggle is worsened if patients have not developed sustainable lifestyle or habit modifications during treatment.
Growing Use
Figures indicate that millions of adults in the UK have tried weight-loss jabs in the past year, with desire remaining high.
- Use is greater among women than males.
- The 40s and 50s demographic shows the highest usage rates.
- A large proportion obtain the drugs through private healthcare rather than the NHS.
Ultimately, researchers emphasize that while these medications are effective tools for shedding pounds, they are not a permanent solution and lasting health benefits hinges on ongoing behavioural management.
